{"id":44,"date":"2023-07-04T15:15:37","date_gmt":"2023-07-04T14:15:37","guid":{"rendered":"http:\/\/tris.sambrownprojects.com\/?page_id=44"},"modified":"2024-05-29T14:12:33","modified_gmt":"2024-05-29T13:12:33","slug":"in-the-news","status":"publish","type":"page","link":"https:\/\/www.trispharma.com\/media\/in-the-news\/","title":{"rendered":"In the News"},"content":{"rendered":"
[vc_row][vc_column][vc_column_text css=”.vc_custom_1692361004917{margin-bottom: 0px !important;}”]
A year-long shortage of ADHD medicine has created an endless loop of millions of parents searching desperately to find medication for their kids \u2014 often on a monthly basis. Monmouth Junction-based Tris Pharma is working to help.[\/vc_column_text][\/vc_column][vc_column width=”1\/2″ el_class=”col-news” conditional_render=”%5B%7B%22value_role%22%3A%22administrator%22%7D%5D”][vc_single_image image=”1850″ img_size=”full” onclick=”custom_link” img_link_target=”_blank” css=”.vc_custom_1716869669812{margin-bottom: 0px !important;}” link=”https:\/\/www.clinicaltrialsarena.com\/features\/pain-clinical-trials\/”][vc_column_text css=”.vc_custom_1716869652477{margin-bottom: 0px !important;}” el_class=”og-typo”]<\/p>\n
Although pain affects millions of people worldwide, the industry is still struggling in the ongoing search for safe and effective medication.[\/vc_column_text][\/vc_column][\/vc_row][vc_row conditional_render=”%5B%7B%22value_role%22%3A%22administrator%22%7D%5D” el_class=”og-rw”][vc_column width=”1\/2″ el_class=”col-news” conditional_render=”%5B%7B%22value_role%22%3A%22administrator%22%7D%5D”][vc_single_image image=”1867″ img_size=”full” onclick=”custom_link” img_link_target=”_blank” css=”.vc_custom_1700660876225{margin-bottom: 0px !important;}” link=”https:\/\/thebioreport.podbean.com\/e\/managing-pain-without-addiction\/”][vc_column_text css=”.vc_custom_1701256295511{margin-bottom: 0px !important;}” el_class=”og-typo”]<\/p>\n
Opioid overdose, abuse, and addiction affect an estimated 3 million Americans and accounts for $35 billion in U.S. healthcare costs every year. Tris Pharma is developing the opioid Cebranopadol, as an effective pain management therapy without the addictive potential of FDA-approved opioids.[\/vc_column_text][\/vc_column][vc_column width=”1\/2″ el_class=”col-news” conditional_render=”%5B%7B%22value_role%22%3A%22administrator%22%7D%5D”][vc_single_image image=”1869″ img_size=”full” onclick=”custom_link” img_link_target=”_blank” css=”.vc_custom_1700660916240{margin-bottom: 0px !important;}” link=”https:\/\/www.lifescienceleader.com\/doc\/to-america-a-new-biopharma-model-0001″][vc_column_text css=”.vc_custom_1716869773369{margin-bottom: 0px !important;}” el_class=”og-typo”]<\/p>\n
Ketan Mehta, founder and CEO of Tris Pharma. Mehta came to the U.S. in the late 1970s. Since then, he has built a career in pharma and, more recently, an entirely new company with a triad of businesses-platform technology licensing, generic medicines, and new drug development.[\/vc_column_text][\/vc_column][\/vc_row][vc_row conditional_render=”%5B%7B%22value_role%22%3A%22administrator%22%7D%5D” el_class=”og-rw”][vc_column width=”1\/2″ el_class=”col-news” conditional_render=”%5B%7B%22value_role%22%3A%22administrator%22%7D%5D”][vc_single_image image=”1857″ img_size=”full” onclick=”custom_link” img_link_target=”_blank” css=”.vc_custom_1700661095660{margin-bottom: 0px !important;}” link=”https:\/\/sleepreviewmag.com\/sleep-treatments\/pharmaceuticals\/prescription-drugs\/navigate-narcolepsy-pharmacotherapy\/”][vc_column_text css=”.vc_custom_1714573894822{margin-bottom: 0px !important;}” el_class=”og-typo”]<\/p>\n
With new narcolepsy drugs available, sleep specialists face the challenge of selecting the most suitable therapies for their patients.[\/vc_column_text][\/vc_column][vc_column width=”1\/2″ el_class=”col-news” conditional_render=”%5B%7B%22value_role%22%3A%22administrator%22%7D%5D”][vc_single_image image=”1859″ img_size=”full” onclick=”custom_link” img_link_target=”_blank” css=”.vc_custom_1700661124885{margin-bottom: 0px !important;}” link=”https:\/\/njbiz.com\/njbiz-conversations-ketan-mehta\/”][vc_column_text css=”.vc_custom_1701255781124{margin-bottom: 0px !important;}” el_class=”og-typo”]<\/p>\n
Tris Pharma founder and CEO Ketan Mehta talks about his company’s work on a new, non-addictive pain treatment and other promising products in the pipeline.[\/vc_column_text][\/vc_column][\/vc_row][vc_row conditional_render=”%5B%7B%22value_role%22%3A%22administrator%22%7D%5D” el_class=”og-rw” css=”.vc_custom_1700655687985{padding-bottom: 50px !important;}”][vc_column width=”1\/2″ el_class=”col-news” conditional_render=”%5B%7B%22value_role%22%3A%22administrator%22%7D%5D”][vc_single_image image=”1861″ img_size=”full” onclick=”custom_link” img_link_target=”_blank” css=”.vc_custom_1700661212076{margin-bottom: 0px !important;}” link=”https:\/\/www.pharmavoice.com\/news\/new-opioid-less-addictive-Tris-Pharma\/652736\/”][vc_column_text css=”.vc_custom_1701256320637{margin-bottom: 0px !important;}” el_class=”og-typo”]<\/p>\n
Tris Pharma\u2019s CEO is \u201cbetting the company\u201d on a pain reliever with the power of an opioid and a lower chance of addiction.[\/vc_column_text][\/vc_column][vc_column width=”1\/2″ el_class=”col-news” conditional_render=”%5B%7B%22value_role%22%3A%22administrator%22%7D%5D”][vc_single_image image=”1863″ img_size=”full” onclick=”custom_link” img_link_target=”_blank” css=”.vc_custom_1700661255440{margin-bottom: 0px !important;}” link=”https:\/\/biobuzz.io\/flying-under-the-radar-tris-pharma-builds-strong-pipeline-in-adhd-pain-neurological-disorders\/”][vc_column_text css=”.vc_custom_1716870568775{margin-bottom: 0px !important;}” el_class=”og-typo”]<\/p>\n
In the continual wake of the opioid crisis gripping the nation, New Jersey-based Tris Pharma is developing a pipeline of pain treatments that are expected to be much safer than currently available products.[\/vc_column_text][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"
[vc_row][vc_column][vc_column_text css=”.vc_custom_1692361004917{margin-bottom: 0px !important;}”][\/vc_column_text][\/vc_column][\/vc_row][vc_row conditional_render=”%5B%7B%22value_role%22%3A%22administrator%22%7D%5D” el_class=”og-rw”][vc_column width=”1\/2″ el_class=”col-news” conditional_render=”%5B%7B%22value_role%22%3A%22administrator%22%7D%5D”][vc_single_image image=”1865″ img_size=”full” onclick=”custom_link” img_link_target=”_blank” css=”.vc_custom_1700660639027{margin-bottom: 0px !important;}” link=”https:\/\/www.roi-nj.com\/2023\/11\/02\/healthcare\/how-n-j-company-tris-pharma-is-working-to-solve-severe-shortage-of-adhd-medication\/”][vc_column_text css=”.vc_custom_1701256278682{margin-bottom: 0px !important;}” el_class=”og-typo”] ROI-NJ How N.J. company, Tris Pharma, is working to solve severe shortage of ADHD medication A year-long shortage of ADHD medicine has created an endless loop of millions of parents searching desperately to find […]<\/p>\n","protected":false},"author":2,"featured_media":0,"parent":38,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":"","_wp_rev_ctl_limit":""},"class_list":["post-44","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"\n